The sGC stimulator riociguat is approved for the treatment of two rare and serious forms of pulmonary hypertension: pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (Ghofrani et al., 2013a; Ghofrani et al., 2013b). The gene discussed is SGCB; the disease is pulmonary hypertension.